# IGF-1 LR3 dosage guide

> Review IGF-1 LR3 dosage information by administration route, with source-linked dose and schedule details.

Canonical: https://pepflow.app/peptides/igf-1-lr3/dosage/

Review IGF-1 LR3 injection amounts, training-day patterns, timing and course lengths for this modified IGF-1 analogue. Calculate volume and syringe units using your own vial inputs.

[Full IGF-1 LR3 library reference](<https://pepflow.app/peptides/igf-1-lr3/>)

## IGF-1 LR3 dosage chart

This summary table compares available dose amounts and schedules by administration route.

| Route | Dose | Frequency & duration |
| --- | --- | --- |
| Injectable | 20–50 mcg | Daily or training days · 4–6 wk |

## IGF-1 LR3 dosage by administration route

### IGF-1 LR3 injectable dosage

Reported-use amounts for IGF-1 LR3 are 20–50 mcg per administration, daily or training days, for 4–6 wk. Reported injectable amounts are 20–40 mcg initially, 50–80 mcg at an intermediate level and 80–100 mcg at a higher level, once daily after exercise for 4–6 weeks. Step intervals and a validated human titration schedule are not specified.[\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>) [\[10\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-10>)

IGF-1 LR3 is a modified IGF-1 analogue with different binding characteristics from native IGF-1. Changes in insulin sensitivity and blood glucose are central considerations with systemic exposure.[\[1\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-3>) [\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>)

### Frequency and timing

Morning or after a workout is the listed injection timing; some patterns use training days rather than every day.[\[4\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-4>) [\[1\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-2>) [\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>)

### Cycle length and breaks

Injectable: 4–6 wk. A standard break interval between courses is not established.[\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>)

## IGF-1 LR3 dosage calculator

Convert your chosen IGF-1 LR3 amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.

For preparation terms and concentration basics, see the [reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>). Follow the arithmetic in the [concentration calculation walkthrough](<https://pepflow.app/blog/how-to-calculate-final-concentration/>).

## IGF-1 LR3 safety and side effects

### Approval and product quality

IGF-1 LR3 is not an FDA-approved drug.[\[4\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-4>) [\[6\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-6>) [\[7\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-7>) [\[8\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-8>)

### Side effects and long-term safety

Systemic IGF-axis exposure can involve glucose symptoms and fluid shifts. Human dose-response, immunogenicity, long-term metabolic effects and product interchangeability remain poorly characterized.[\[5\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-5>)

### Route-specific dosing limits

Glucose control, growth-factor-sensitive conditions, injectable product quality and anti-doping restrictions require separate attention. Reported-use injectable schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[\[5\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-5>) [\[10\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-10>) [\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>)

## Common IGF-1 LR3 dosage questions

### Is there a standard human dose of IGF-1 LR3?

A transferable human dose for IGF-1 LR3 has not been established. A product strength or reminder amount does not establish a treatment regimen.[\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>)

### What dosage is listed for IGF-1 LR3?

Reported-use amounts for IGF-1 LR3 are 20–50 mcg per administration, daily or training days, for 4–6 wk.[\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>) [\[10\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-10>)

### Does IGF-1 LR3 have a standard cycle or break interval?

Injectable: 4–6 wk. A standard break interval between courses is not established.[\[9\]](<https://pepflow.app/peptides/igf-1-lr3/dosage/#source-9>)

## Sources

- [\[1\] **IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.** Am J Physiol Endocrinol Metab, 2025 Jan 1. animal.](<https://pubmed.ncbi.nlm.nih.gov/39679943/>)
- [\[2\] **Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.** J Dev Orig Health Dis, 2023 Jun. animal.](<https://pubmed.ncbi.nlm.nih.gov/37114757/>)
- [\[3\] **Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers.** Domest Anim Endocrinol, 1999 May. animal.](<https://pubmed.ncbi.nlm.nih.gov/10370861/>)
- [\[4\] **Search Drugs@FDA for IGF-1 LR3** U.S. Food and Drug Administration. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[5\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[6\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[7\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[8\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[9\] **PepFlow peptide cheat sheet — reported-use and product-orientation reference (not clinical research)** PepFlow. reference catalog.](<https://pepflow.app/peptide-cheat-sheet/>)
- [\[10\] **IGF-1 LR3 — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-igf-1-lr3.html>)

[Full IGF-1 LR3 library reference →](<https://pepflow.app/peptides/igf-1-lr3/>)

## Related

- [IGF-1 LR3 Peptide](<https://pepflow.app/peptides/igf-1-lr3/>)
- [Peptide reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>)
- [How to Calculate Final Concentration: A Practical Guide](<https://pepflow.app/blog/how-to-calculate-final-concentration/>)
- [Peptide Cheat Sheet](<https://pepflow.app/peptide-cheat-sheet/>)
